Published in PLoS One on February 06, 2014
A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. J Proteomics (2016) 0.80
Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. J Proteome Res (2015) 0.80
Integrated glycomic analysis of ovarian cancer side population cells. Clin Proteomics (2016) 0.79
Identification of aberrantly expressed glycans in gastric cancer by integrated lectin microarray and mass spectrometric analyses. Oncotarget (2016) 0.77
Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients. Oncotarget (2016) 0.76
Determination of true ratios of different N-glycan structures in electrospray ionization mass spectrometry. Anal Bioanal Chem (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Glycosylation in cellular mechanisms of health and disease. Cell (2006) 8.45
The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer (2005) 5.98
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res (2008) 3.85
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res (2003) 2.91
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Diversity in cell surface sialic acid presentations: implications for biology and disease. Lab Invest (2007) 2.64
Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med (2000) 2.61
Glycomics hits the big time. Cell (2010) 2.56
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res (2008) 2.35
Protein glycosylation in development and disease. Bioessays (1999) 2.32
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res (2005) 2.08
Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res (1993) 2.07
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Sialyltransferases in cancer. Glycoconj J (2003) 1.83
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Glycomics profiling of Chinese hamster ovary cell glycosylation mutants reveals N-glycans of a novel size and complexity. J Biol Chem (2009) 1.58
Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics (2010) 1.52
Adaptive regulation at the cell surface by N-glycosylation. Traffic (2009) 1.50
Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res (2002) 1.48
N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res (2012) 1.46
Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci U S A (1995) 1.44
Secretome proteomics for discovery of cancer biomarkers. J Proteomics (2010) 1.44
Introduction of bisecting GlcNAc into integrin alpha5beta1 reduces ligand binding and down-regulates cell adhesion and cell migration. J Biol Chem (2004) 1.44
Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem (1996) 1.44
Quantitation by isobaric labeling: applications to glycomics. J Proteome Res (2007) 1.34
Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev (2012) 1.32
N-acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J Biol Chem (2003) 1.31
The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer (2008) 1.31
Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. Carbohydr Res (2009) 1.24
Quantification of the N-glycosylated secretome by super-SILAC during breast cancer progression and in human blood samples. Mol Cell Proteomics (2012) 1.24
Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res (2005) 1.23
N-acetylglucosaminyltransferase III antagonizes the effect of N-acetylglucosaminyltransferase V on alpha3beta1 integrin-mediated cell migration. J Biol Chem (2006) 1.22
Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics (2010) 1.16
Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochim Biophys Acta (2003) 1.15
IDAWG: Metabolic incorporation of stable isotope labels for quantitative glycomics of cultured cells. J Proteome Res (2009) 1.15
Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics (2011) 1.14
A mutual regulation between cell-cell adhesion and N-glycosylation: implication of the bisecting GlcNAc for biological functions. J Proteome Res (2009) 1.12
Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol (2010) 1.11
Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG (2007) 1.10
The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum Mol Genet (2009) 1.09
The cancer cell secretome: a good source for discovering biomarkers? J Proteomics (2010) 1.09
Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochim Biophys Acta (2001) 1.08
Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells. Clin Exp Metastasis (2003) 1.08
A strategy for identification of oligosaccharide structures using observational multistage mass spectral library. Anal Chem (2005) 1.06
The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res (2010) 1.05
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res (2011) 1.05
N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin. Glycobiology (2010) 1.03
The bisecting GlcNAc in cell growth control and tumor progression. Glycoconj J (2012) 1.02
Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res (2010) 1.01
Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. Adv Exp Med Biol (1986) 0.93
Purification and characterization of UDP-N-acetylglucosamine: alpha-6-D-mannoside beta 1-6N-acetylglucosaminyltransferase (N-acetylglucosaminyltransferase V) from a human lung cancer cell line. J Biochem (1993) 0.93
Glycosylation effects on cancer development. Glycoconj J (2012) 0.93
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization. Cancer Res (1996) 0.90
Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer. Sao Paulo Med J (2002) 0.89
Overexpression of N-acetylglucosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up-regulation of the internalization rate of the receptors. J Biol Chem (2000) 0.88
LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. J Proteome Res (2010) 0.88
Comparative glycomic profiling of isotopically permethylated N-glycans by liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.87
A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J (Engl) (2003) 0.87
Beta1,4-N-Acetylglucosaminyltransferase III down-regulates neurite outgrowth induced by costimulation of epidermal growth factor and integrins through the Ras/ERK signaling pathway in PC12 cells. Glycobiology (2003) 0.87
Quantitative glycomics strategies. Mol Cell Proteomics (2013) 0.85
Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells. Int J Biochem Cell Biol (2012) 0.84
Sampling the omentum in ovarian neoplasia: when one block is enough. Int J Gynecol Cancer (2006) 0.84
Gene transfection-mediated overexpression of beta1,4-N-acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function. J Biol Chem (1997) 0.83
Endoglycosidase-mediated incorporation of 18O into glycans for relative glycan quantitation. Anal Chem (2011) 0.82
Site-specific N-glycosylation identification of recombinant human lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). Glycoconj J (2012) 0.80
Quantitative analysis of glycoprotein glycans. Methods Mol Biol (2013) 0.78
Glycomic analysis of ovarian cancer: past, present, and future. Cancer Biomark (2011) 0.77
Trihydrophobin 1 phosphorylation by c-Src regulates MAPK/ERK signaling and cell migration. PLoS One (2012) 0.76
Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma. Oncotarget (2014) 0.82